SEARCH

SEARCH BY CITATION

References

  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 9197.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 21232132.
  • Ellis, J.H., Barber, K.A., Tutt, A., Hale, C., Lewis, A.P., Glennie, M.J., Stevenson, G.T. & Crowe, J.S. (1995) Engineered anti-Cd38 monoclonal-antibodies for immunotherapy of multiple-myeloma. Journal of Immunology, 155, 925937.
  • Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. & Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 29202924.
  • Ghobrial, I.M., Otteman, L.A. & White, W.L. (2003) An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. New England Journal of Medicine, 349, 25702572. discussion 2570–2572.
  • Giles, F.J., Vose, J.M., Do, K.A., Johnson, M.M., Manshouri, T., Bociek, G., Bierman, P.J., O’Brien, S.M., Keating, M.J., Kantarjian, H.M., Armitage, J.O. & Albitar, M. (2003) Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. British Journal of Haematology, 123, 850857.
  • Goldman, J.P., Blundell, M.P., Lopes, L., Kinnon, C., Di Santo, J.P. & Thrasher, A.J. (1998) Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. British Journal of Haematology, 103, 335342.
  • Greenaway, S., Henniker, A.J., Walsh, M. & Bradstock, K.F. (1994) A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia. Leukaemia & Lymphoma, 13, 323331.
  • Gribben, J.G. & Hallek, M. (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. British Journal Haematology, 144, 818831.
  • Hadari, Y. & Schlessinger, J. (2009) FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. Journal of Clinical Investigation, 119, 10771079.
  • Herbert, K.E., Prince, H.M. & Westerman, D.A. (2003) Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood, 101, 1654.
  • Herlyn, D. & Koprowski, H. (1982) IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proceedings of the National Academy of Sciences of the United States of America, 79, 47614765.
  • Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G. & Anderson, K.C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 7, 585598.
  • Hillmen, P., Skotnicki, A.B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C. & Mayer, J. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 56165623.
  • Hsi, E.D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B.P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A.G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, J.D., Jr, Barlogie, B., van Rhee, F., Hussein, M., Afar, D.E. & Williams, M.B. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research, 14, 27752784.
  • Katagiri, S., Yonezawa, T., Kuyama, J., Kanayama, Y., Nishida, K., Abe, T., Tamaki, T., Ohnishi, M. & Tarui, S. (1985) Two distinct human myeloma cell lines originating from one patient with myeloma. International Journal of Cancer, 36, 241246.
  • Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 35543561.
  • Kluin-Nelemans, H.C., Coenen, J.L., Boers, J.E., van Imhoff, G.W. & Rosati, S. (2008) EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood, 112, 10391041.
  • Kyle, R.A. & Rajkumar, S.V. (2004) Multiple myeloma. New England Journal of Medicine, 351, 18601873.
  • Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. & Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 24572466.
  • Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. & Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology, 23, 29712979.
  • O’Brien, S., Ravandi, F., Riehl, T., Wierda, W., Huang, X., Tarrand, J., O’Neal, B., Kantarjian, H. & Keating, M. (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood, 111, 18161819.
  • Ocio, E.M., Mateos, M.V., Maiso, P., Pandiella, A. & San-Miguel, J.F. (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncology, 9, 11571165.
  • Palumbo, A. & Anderson, K. (2011) Multiple myeloma. New England Journal of Medicine, 364, 10461060.
  • Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G. & Anderson, K.C. (2009) Multiple myeloma. Lancet, 374, 324339.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 26092617.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 15651571.
  • Sintes, J., Romero, X., Marin, P., Terhorst, C. & Engel, P. (2008) Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. Experimental Hematology, 36, 11991204.
  • Smith, G.M., Biggs, J., Norris, B., Anderson-Stewart, P. & Ward, R. (1997) Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis. Journal of Clinical Immunology, 17, 502509.
  • Stevenson, G.T. (2006) CD38 as a therapeutic target. Molecular Medicine, 12, 345346.
  • Stevenson, F.K., Bell, A.J., Cusack, R., Hamblin, T.J., Slade, C.J., Spellerberg, M.B. & Stevenson, G.T. (1991) Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-Cd38 antibody. Blood, 77, 10711079.
  • Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R.F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M. & Dohner, H. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German chronic lymphocytic leukemia study group. Journal of Clinical Oncology, 27, 39944001.
  • Sun, H., Norris, B.J., Atkinson, K., Biggs, J.C. & Smith, G.M. (1998) Preclinical antitumor activity of an antibody against the leukocyte antigen CD48. Clinical Cancer Research, 4, 895900.
  • Sun, H., Biggs, J.C. & Smith, G.M. (2000) Antitumour activity of a chimeric antibody against the leucocyte antigen CD48. Cancer Immunology, Immunotherapy, 48, 595602.
  • Tai, Y.T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N.C., Luqman, M. & Anderson, K.C. (2005) Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research, 65, 58985906.
  • Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weller, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. & Anderson, K.C. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 13291337.
  • Tai, Y.T., de Weers, M., Li, X.F., Song, W.H., Nahar, S., Bakker, J.M., Vink, T., Jacobs, D., Oomen, L., Bleeker, W.K., Munshi, N.C., van de Winkel, J.G.J., Parren, P.W.H.I., Richardson, P. & Anderson, K.C. (2009) Daratumumab, a novel potent human anti-CD38 monoclonal antibody, induces significant killing of human multiple myeloma cells: therapeutic implication. Blood, 114, 252252.
  • Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. & Anderson, K.C. (2004a) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood, 104, 36883696.
  • Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. & Munshi, N.C. (2004b) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Research, 64, 46294636.
  • Vaughan, H.A., Thompson, C.H., Sparrow, R.L. & McKenzie, I.F. (1983) Hu Ly-M3-a human leukocyte antigen. Transplantation, 36, 446450.
  • van der Veer, M.S., de Weers, M., van Kessel, B., Bakker, J.M., Wittebol, S., Parren, P.W.H.I., Lokhorst, H.M. & Mutis, T. (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica, 96, 284290.
  • Wang, J., Kimura, T., Asada, R., Harada, S., Yokota, S., Kawamoto, Y., Fujimura, Y., Tsuji, T., Ikehara, S. & Sonoda, Y. (2003) SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood, 101, 29242931.
  • de Weers, M., Tai, Y.T., van der Veer, M.S., Bakker, J.M., Vink, T., Jacobs, D.C.H., Oomen, L.A., Peipp, M., Valerius, T., Slootstra, J.W., Mutis, T., Bleeker, W.K., Anderson, K.C., Lokhorst, H.M., van de Winkel, J.G.J. & Parren, P.W.H.I. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology, 186, 18401848.
  • Yang, J., Qian, J., Wezeman, M., Wang, S., Lin, P., Wang, M., Yaccoby, S., Kwak, L.W., Barlogie, B. & Yi, Q. (2006) Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10, 295307.